Something shifted in men's health over the last two years. When Sir Chris Hoy went public about his diagnosis in early 2024, the effect was immediate and measurable. Medichecks recorded its highest ever month for prostate cancer screens that October, with more than double the usual number of men coming forward. By mid-2025, polling for Healthwatch found that most men in England would attend a national screening programme if one were offered.
Then, this month, Jeremy Clarkson did it again. In the finale of Clarkson's Farm he revealed an aggressive prostate cancer, caught early enough to treat, and followed it with a characteristically blunt message to camera: he is perfectly fine only because the doctors found it early, so men should stop making excuses and get tested. It is, he reminded several million viewers, just a blood test these days.
The conversation clinicians had wanted for two decades has finally arrived, driven not by a guideline but by a cyclist and a farmer talking honestly about their own bodies. That is the good news. The complication is what men actually walk into when they act on it. And the irony sits right inside Clarkson's rallying cry. He is right that men should come forward. He is also pointing them straight at the weakest part of the whole pathway.
The PSA test is doing a job it was never built for
The front door to prostate cancer diagnosis in the UK is the prostate-specific antigen blood test. It is cheap, quick and widely available, and for a man newly motivated to check his health it feels like the obvious first step. The problem is that PSA is a blunt instrument wearing the uniform of a precise one.
PSA does not measure cancer. It measures a protein that rises with prostate cancer but also with benign enlargement, infection, recent exercise and plenty else besides. That gives it two failure modes, and both matter.
False positives are common. A raised PSA sends a man down a pathway of anxiety and, historically, an invasive biopsy he may never have needed. The majority of men with an elevated PSA turn out not to have clinically significant cancer. The biopsy itself carries real risk, including infection and sepsis.
False negatives are quieter but more dangerous. Around 15 per cent of men with a PSA in the normal range still have prostate cancer, and about 2 per cent have high-grade disease. A reassuring blood test can send the wrong man home.
PSA also cannot tell the difference between the cancer that will kill a man and the one he will comfortably die with. Most prostate cancers are slow. Detect them indiscriminately and you push men towards surgery or radiotherapy whose side effects, incontinence and erectile dysfunction among them, can be worse than the disease they were meant to treat.
This is not a fringe view. When the UK National Screening Committee published its decision in November 2025, it again declined to recommend population-wide screening, and the reasoning turned almost entirely on the test at the front of the pathway. The committee's own summary described PSA as a poor test for prostate cancer and said a more specific test was needed. It approved targeted screening only for the small group of men carrying a BRCA2 gene variant, where the evidence of early aggressive disease is strongest.
It would be easy to read that as the system saying no to early detection. It is not. It is the system saying that a screening programme is only as safe as its weakest test, and PSA on its own is the weak link. The committee is now waiting on TRANSFORM, the £42 million trial recruiting up to 300,000 men, which is explicitly testing better tools, including fast MRI scans, to fill that gap.
Where MRI changes the maths
Here is the part of the story that often gets lost in the screening debate. The better test the committee is asking for is not a future invention. For the central problem, it already exists, and it is sitting in radiology departments today.
Multiparametric MRI, used before biopsy rather than after, is the closest thing the field has to a safety net. Two landmark UK trials made the case and changed practice.
In PROMIS, mpMRI picked up clinically significant cancer with a sensitivity of 93 per cent, against just 48 per cent for the old standard transrectal ultrasound biopsy. Used as a triage step, it meant around 27 per cent of men could safely avoid a biopsy altogether, while up to 18 per cent more significant cancers were caught and fewer trivial ones were over-diagnosed.
PRECISION then tested the pathway head to head. Men sent for MRI first, with a targeted biopsy only where the scan flagged something, had significantly more important cancers found (38 per cent versus 26 per cent) and far fewer insignificant ones. More than a quarter of men whose scans were clear avoided an unnecessary biopsy entirely.
On the strength of evidence like this, NICE now recommends mpMRI as the first-line investigation for suspected localised prostate cancer. Scans are read using the standardised PI-RADS scoring system, which grades the likelihood of significant disease and gives clinicians a consistent language to act on. A clear scan can reliably rule significant cancer out. A suspicious one tells the biopsy needle exactly where to look instead of sampling blind.
The pathway awareness actually needs
Put those pieces together and the role of each test becomes clear.
PSA is the spark. It is the cheap, accessible signal that prompts a man to come forward and a clinician to look closer. That job it does well enough, which is exactly why the awareness surge has value.
MRI is the filter. It takes the noisy PSA signal and sorts it: ruling out the men who can be safely reassured, sparing them a biopsy they never needed, and pointing precisely at the men who genuinely require one. It catches the aggressive cancers PSA alone would miss and ignores the indolent ones PSA alone would over-treat.
Biopsy, in this model, becomes the targeted final step rather than the routine second one. Fewer men have it, the men who do get a better one, and the whole pathway produces less harm and more accurate answers.
That is the safety net. Not a slogan, but a measurable reduction in unnecessary biopsies, a measurable increase in significant cancers found, and a measurable fall in over-diagnosis. It is the difference between awareness that simply generates more anxious men in waiting rooms and awareness that actually saves lives without a trail of avoidable harm behind it.
The point
The screening committee was right that a national programme built on PSA alone would do more harm than good. That is a statement about the test, not about the ambition. Men are coming forward in numbers the system has never seen, and they deserve a pathway that matches their willingness to act.
The encouraging truth is that the missing piece is already here. MRI before biopsy is proven, recommended and available now. The men reaching for a PSA test because a cyclist and a farmer told them to are doing the right thing. The job for the rest of us is to make sure the safety net is waiting for them when they do.
You do not have to wait for a national programme to get the safety net. Our prostate pathway offers specialist-reported prostate MRI scans, from £599, start with your PSA.